New Products

fentanyl nasal

Still no tangible advantage of intranasal administration

- No better than immediate-release oral morphine in a trial including 84 patients, but more frequent adverse effects. Risk of overdose due to confusion between the different forms and doses of fentanyl.

Immediate-release oral morphine is the standard option for cancer patients with breakthrough pain despite appropriate opioid therapy (1). Alternatives include three forms of buccal fentanyl (1). There is no evidence that intranasal fentanyl (Instanyl®) is more effective or better tolerated than buccal fentanyl. Mid 2011, the packaging posed a risk for both patients and caregivers (1).

A second form of fentanyl nasal spray (Pecfent®, Archimedes) has been announced. The solution contains pectin and sucrose and is designed to form a gel coating on the nasal mucosa after application (2). The following article examines whether this second intranasal fentanyl product provides more rapid or more effective relief than immediate-release oral morphine or buccal fentanyl for cancer patients with breakthrough pain, and whether the packaging of Pecfent® is better designed than that of Instanyl®.

A trial versus immediate-release oral morphine. In addition to a placebo-controlled trial (although ethically unacceptable in this setting), the new form of intranasal fentanyl has been evaluated in a small trial (84 patients) versus immediate-release oral morphine (a)(2,3). In the 79 patients who completed the trial, the mean difference in pain intensity, assessed 15 minutes post-dose on a 10-point rating scale (primary endpoint), was 3.0 points in the intranasal fentanyl group versus 2.7 points in the morphine group (3). Although statistically signifi-
cant, this slight difference is not clinically relevant.

Adverse effects (mainly vomiting, drowsiness, dehydration and nausea) occurred in about half of the patients treated with intranasal fentanyl, versus 16% of those treated with morphine (3). Three patients treated with intranasal fentanyl experienced serious adverse effects (hypotension, heart failure, and anuria), versus none in the morphine group (3).

About one-quarter of the 523 patients treated with intranasal fentanyl in clinical trials experienced opioid-related adverse effects or effects associated with nasal administration (epistaxis, runny nose, or nasal discomfort) (2).

Better-designed packaging but an incomplete dose range. Pecfent® is sold in multidose spray bottles equipped with a metered-dose pump that has to be primed for initial use, as with Instanyl®. The pump has a spray counter so that the patient can hear a click and see that the pump has been primed, and track the number of doses administered. This is an advantage, but a system ensuring a lock-out period between two doses would also be useful.

The lack of a 300-μg dose strength rules out the use of doses of 300 or 600 μg.

In clinical trials, 8% to 16% of patients had difficulty using the device (2). Only the box, and not the bottle, is child-resistant.

Used bottles are to be returned to a pharmacy for disposal (4). They must not be placed in the household waste because they still contain enough fentanyl to cause harm.

The increased number of fentanyl products and dose strengths represents a source of confusion and overdose, especially as the different formulations are not bioequivalent (1,4).

fentanyl

Pecfent®

Nasal spray solution

- 100 μg or 400 μg of fentanyl per spray

Opioid analgesic

- Indication: “breakthrough pain (BTP) in adults who are already receiving maintenance opioid therapy for chronic cancer pain”.

[EU marketing authorisation, centralised procedure]

In practice. It is better to prescribe immediate-release oral morphine, or possibly buccal fentanyl, to cancer patients with breakthrough pain.

Selected references from Prescrire’s literature search.